SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Form 8.3 - CSR PLC - Replacement

28 Nov 2014 11:31

The issuer advises that the following replaces the BARCLAYS PLC Form 8.3 - CSR PLC announcement released on 27 November 2014 at 14.53 GMT.

The ticker information has been corrected to reference the information for the company CSR Plc instead of that of Consort Medical, which was erroneously included and should be disregarded.

All other details remain unchanged.

The full corrected version is shown below.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Identity of the person whose positions/dealings Barclays PLC.
are being disclosed:
(b) Owner or controller of interest and short
positions disclosed, if different from 1(a):
(c) Name of offeror/offeree in relation to whose

CSR PLC

relevant securities this form relates:
(d) If an exempt fund manager connected with an
offeror/offeree, state this and specify identity of
offeror/offeree:
(e) Date position held/dealing undertaken: 26 November 2014
(f) Has the discloser previously disclosed, or are NO
they today disclosing, under the Code in respect
of any other party to this offer?

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: ORD
Interests Short Positions
Number (%) Number (%)
(1) Relevant securities owned
and/or controlled: 4,887,599 2.94% 122,884 0.07%
(2) Derivatives (other than
options): 126 0.00% 3,362,849 2.03%
(3) Options and agreements to
purchase/sell: 0 0.00% 0 0.00%
(4)
TOTAL: 4,887,725 2.94% 3,485,733 2.10%

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit
security securities
ORD Purchase 100 8.2350 GBP
ORD Purchase 248 8.2300 GBP
ORD Purchase 293 8.2275 GBP
ORD Purchase 376 8.2600 GBP
ORD Purchase 708 8.2500 GBP
ORD Purchase 1,118 8.2498 GBP
ORD Purchase 1,227 8.2467 GBP
ORD Purchase 1,263 8.2531 GBP
ORD Purchase 1,569 8.2450 GBP
ORD Purchase 2,328 8.2436 GBP
ORD Purchase 4,881 8.2405 GBP
ORD Purchase 5,347 8.2429 GBP
ORD Purchase 6,086 8.2603 GBP
ORD Purchase 6,097 8.2513 GBP
ORD Purchase 10,762 8.2394 GBP
ORD Sale 44 8.1950 GBP
ORD Sale 124 8.2300 GBP
ORD Sale 293 8.2275 GBP
ORD Sale 305 8.2500 GBP
ORD Sale 390 8.2600 GBP
ORD Sale 1,846 8.2400 GBP
ORD Sale 1,995 8.2514 GBP
ORD Sale 10,317 8.2364 GBP
ORD Sale 19,920 8.2405 GBP

(b) Derivatives transactions (other than options)

Class of Product Nature of dealing Number of Price per
relevant description reference unit
security securities
ORD SWAP Long 2,372 8.2382 GBP
ORD CFD Long 2,777 8.2386 GBP
ORD CFD Long 7,431 8.2362 GBP
ORD CFD Short 1,118 8.2498 GBP
ORD SWAP Short 1,482 8.2488 GBP
ORD SWAP Short 2,212 8.2479 GBP
ORD CFD Short 5,347 8.2429 GBP
ORD SWAP Short 6,086 8.2604 GBP
ORD CFD Short 5,235 8.2532 GBP

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type

e.g. American, European etc.

Expiry date Option money paid/ received per unit

(ii) Exercising

Class of relevant security Product description

e.g. call option

Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state “none”

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 27 Nov 2014
Contact name: Sushil Vashisht
Telephone number: 0207 773 0744

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Copyright Business Wire 2014

Date   Source Headline
8th Apr 20159:57 amRNSDirector Declaration
1st Apr 20159:07 amRNSTotal Voting Rights
23rd Mar 20152:44 pmRNSHolding(s) in Company
12th Mar 20152:53 pmRNSHolding(s) in Company - Replacement
11th Mar 20159:10 amRNSHolding(s) in Company
23rd Feb 20157:00 amRNSVoke® licence - variation granted by MHRA
11th Feb 201511:12 amRNSDirectorate Change
4th Feb 20157:00 amRNSIntegrated Dose Counter Supply Agreement
3rd Feb 201511:37 amRNSHolding(s) in Company
2nd Feb 20159:43 amRNSTotal Voting Rights
29th Jan 20157:00 amRNS£2.2m investment in Atlas Genetics Series C
26th Jan 201512:47 pmRNSDirector/PDMR Shareholding
6th Jan 20153:48 pmRNSDirector/PDMR Shareholding
5th Jan 20152:46 pmRNSTotal Voting Rights
9th Dec 201410:37 amRNSDirector/PDMR Shareholding
4th Dec 20147:00 amRNSHalf Yearly Report
2nd Dec 20141:43 pmRNSBlocklisting Interim Review
28th Nov 201411:31 amBUSForm 8.3 - CSR PLC - Replacement
27th Nov 20142:53 pmBUSForm 8.3 - CSR PLC
27th Nov 20149:00 amRNSHolding(s) in Company
14th Nov 20142:23 pmRNSHolding(s) in Company
12th Nov 201411:09 amRNSAcquisition of Aesica Holdco Limited
12th Nov 201410:06 amRNSTotal Voting Rights
7th Nov 201410:23 amRNSHolding(s) in Company
6th Nov 201412:58 pmRNSHolding(s) in Company
5th Nov 201412:26 pmRNSAdditional Listing
5th Nov 201410:04 amRNSHolding(s) in Company
4th Nov 201412:45 pmRNSTotal Voting Rights
4th Nov 201412:36 pmRNSDirector/PDMR Shareholding
3rd Nov 20149:35 amRNSResults of Rump Placing
3rd Nov 20147:00 amRNSResults of Rights Issue
29th Oct 20144:51 pmRNSDirector/PDMR Shareholding
28th Oct 20145:02 pmRNSHolding(s) in Company
22nd Oct 20147:00 amRNSDevelopment Contract Award
21st Oct 20142:28 pmRNSGerman anti-trust clearance
17th Oct 20148:02 amRNSADMISSION OF NEW ORDINARY SHARES
16th Oct 201412:00 pmRNSResult of EGM
15th Oct 20141:30 pmRNSBlocklisting Interim Review
6th Oct 201410:19 amRNSDirector/PDMR Shareholding
2nd Oct 20141:55 pmRNSHolding(s) in Company
1st Oct 201411:47 amRNSTotal Voting Rights
30th Sep 20143:44 pmRNSPublication of Prospectus
30th Sep 20147:00 amRNSProposed acquisition of Aesica Holdco Limited
12th Sep 20147:00 amRNSMHRA Authorisation of the Voke Inhaler
5th Sep 20143:06 pmRNSHolding(s) in Company
4th Sep 20143:28 pmRNSResult of AGM
4th Sep 20147:00 amRNSInterim Management Statement
29th Jul 20144:28 pmRNSDirector/PDMR Shareholding
29th Jul 201412:10 pmRNSAnnual Financial Report
25th Jul 201410:45 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.